Hansoh Pharmaceutical (03692.HK): HS-10587 Tablet Receives NMPA Approval for Clinical Trials

Hansoh Pharma (03692) announced that HS-10587, a self-developed Class 1 new drug by the Group, has received clinical trial approval from China's National Medical Products Administration (NMPA) for the treatment of advanced solid tumors with MTAP deletion.